US Coverage

Law360 Authority | Deep News & Analysis

Global Coverage

Law360 Pulse | The Business of Law

Mealeys

MLex

Mylan Tries To Escape Pharmacy's EpiPen Antitrust Suit

By Meghan Kelly · December 15, 2020, 5:46 PM EST

Mylan Pharmaceuticals has urged a Kansas federal judge to drop it from a suit alleging it inflated the price for the emergency allergy medication EpiPen, arguing the retail and online pharmacy...

To view the full article, register now.
Try a seven day FREE Trial

Already a subscriber? Click here to login

Documents

Related Sections

Case Information

Case Title

In Re: Epipen (Epinephrine Injection, USP) Marketing, Sales Practices and Antitrust Litigation

Case Number

2:17-md-02785

Court

Kansas

Nature of Suit

Personal Inj. Prod. Liability

Date Filed

August 04, 2017

Case Title

KPH Healthcare Services, Inc. v. Mylan N.V. et al

Case Number

2:20-cv-02065

Court

Kansas

Nature of Suit

Anti-Trust

Date Filed

February 14, 2020

Featured Stories

Medical Marijuana Industry Grapples With DEA's New Role No Photo Available

Sam Reisman

After years of allowing the state-sanctioned medical marijuana industry to operate without interference, the U.S. Drug Enforcement Adm... (more story)

What Kaiser's D&O Win Means For 'Return Of Funds' Fights No Photo Available

Abraham Gross

A California federal judge's ruling that the Kaiser Foundation Health Plan was not automatically prohibited from claiming coverage for... (more story)

Merck Drug Price Row Loss, $56M Biotech Verdict And More No Photo Available

Gianna Ferrarin

Law360 Healthcare Authority looks at a D.C. federal court's rejection of Merck's challenge to the Medicare drug price negotiation prog... (more story)